Sling Therapeutics doses first patients in Phase 3 ORBIT trial of linsitinib for thyroid eye disease

PUBT · 3d ago
Sling Therapeutics doses first patients in Phase 3 ORBIT trial of linsitinib for thyroid eye disease
  • Forbion portfolio company Sling Therapeutics dosed the first patients in its global Phase 3 ORBIT pivotal trial of linsitinib for thyroid eye disease.
  • ORBIT targets about 130 adults with moderate to severe active disease, testing oral linsitinib 150 mg twice daily versus placebo for 24 weeks.
  • Primary readout focuses on proptosis response at Week 24, defined as at least a 2 mm reduction without worsening in the fellow eye.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein.